Osimertinib
- PDF / 168,811 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 21 Downloads / 152 Views
1 S
Development of drug resistance in lung carcinoma: case report In a study, a patient [age and sex not stated] was described, who developed resistance to osimertinib during treatment of nonsmall cell lung carcinoma. The patient showed MET amplification, EGFR T790M and FBXL7 SNV during disease progression. These mutations were not found at baseline [route, dosage, duration of treatment to reaction onset and outcome not stated]. Ju C, et al. Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumour DNA. Annals of Oncology : abstr. 1356P, 803506156 Sep 2020. Available from: URL: http://doi.org/10.1016/j.annonc.2020.08.1670 [abstract]
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
